Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

doi:10.3748/wjg.v31.i29.109947

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (82)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-5)

Sum=81

Aug 7, 2025 (publication date) through Aug 5, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Aug 7, 2025; 31(29): 109947
Published online Aug 7, 2025. doi: 10.3748/wjg.v31.i29.109947

Full Size Figure Download Figure

Figure 3 Propensity score-matching analysis in progression-free survival. A: After propensity score-matching analysis in progression-free survival (PFS) (ratio = 4); B: After propensity score-matching analysis in PFS (ratio = 3); C: After propensity score-matching analysis in PFS (ratio = 2); D: After propensity score-matching analysis in PFS (ratio = 1); E: After inverse probability of treatment weighting analysis (PFS). TP: Targeted therapy combined with anti-programmed cell death 1 immunotherapy; TB: Bevacizumab.

Citation: Gao Z, Wang XY, Song T, Shen ZG, Wang XY, Wu SK, Jin X. Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer. World J Gastroenterol 2025; 31(29): 109947
URL: https://www.wjgnet.com/1007-9327/full/v31/i29/109947.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i29.109947